Btk
Bruton tyrosine kinase
Bruton tyrosine kinase (Btk) is a member of the Tec family kinases with a well-characterized role in B-cell antigen receptor (BCR)-signaling and B-cell activation.
Btk plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity. Btk is a kinase expressed exclusively in B cells and myeloid cells and has a well characterized, vital role in B cells highlighted by the human primary immune deficiency disease, X-linked agammaglobulinemia (XLA), which results from mutation in the Btk gene. Btk plays an essential role in the BCR signaling pathway. Antigen binding to the BCR results in B cell receptor oligomerization, Syk and Lyn kinase activation, followed by Btk kinase activation. Once activated, Btk forms a signaling complex with proteins such as BLNK, Lyn, and Syk and phosphorylates phospholipase C (PLC)γ2. This leads to downstream release of intracellular Ca2+ stores and propagation of the BCR signaling pathway through extracellular signal-regulated kinase and NF-κB signaling, ultimately resulting in transcriptional changes to foster B cell survival, proliferation, and/or differentiation.
All Product Categories
-
Btk Related Products (268)
Related Products (268)
-
Recombinant Proteins (19)
-
Antibodies (3)
-
PROTAC BTK Degrader-13
0 ImagesCat. No.: HY-168963PROTAC BTK Degrader-13 is a reagent targeting BTK, with a DC50 of 0.27 μM. PROTAC BTK Degrader-13 degrades BTK in a proteasome-dependent manner and inhibits BTK-mediated downstream signaling pathways by reducing the phosphorylation levels of BTK and p38 MAPK. PROTAC BTK Degrader-13 exerts selective cytotoxic effects on BTK-overexpressing lymphoma cells and ITK-positive cells. PROTAC BTK Degrader-13 can be used in studies related to B-cell lymphoma.
-
IQS-019
0 ImagesCat. No.: HY-124605CAS No.: 1630804-24-8IQS-019 is a B cell receptor (BCR) kinase inhibitor. IQS-019 can inhibit the de-phosphorylation of constitutive and IgM-activated Syk, Lyn, and Btk. IQS-019 can inhibit cell proliferation, migration and induce apoptosis. IQS-019 exhibits antitumor activity and can be used for the research of cancer, such as B cell lymphoma.
-
BTK V416L Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70809Bruton's tyrosine kinase (BTK) plays a vital role in B-cell antigen receptor (BCR) signalling transduction pathway. BTK can be used for the study of lymphomas and autoimmune diseases. BTK has multiple mutants. BTK V416L Recombinant Human Active Protein Kinase is a recombinant BTK V416L protein that can be used to study BTK V416L-related functions.
-
JAK3/BTK-IN-1
0 ImagesCat. No.: HY-143716CAS No.: 2674036-91-8JAK3/BTK-IN-1 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-1 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 002).
-
PCI-33380 (Standard)
0 ImagesCat. No.: HY-100335RCAS No.: 1022899-36-0PCI-33380 (Standard) is the analytical standard of PCI-33380 (HY-100335). This product is intended for research and analytical applications. PCI-33380 is a fluorescent probe ( (Ex=532 nm, Em=555 nm). PCI-33380 consists of a (BTK) inhibitor PCI-32765 (HY-10997) attaching with a Bodipy-FL fluorophore via a piperazine linker. PCI-33380 binds predominantly to Btk in B cell lysates with cell permeable activity. PCI-33380 can be used for imaging live cancer cells such as non-Hodgkin lymphoma research
-
BMS-935177 (Standard)
0 ImagesCat. No.: HY-101793RCAS No.: 1231889-53-4BMS-935177 (Standard) is the analytical standard of BMS-935177 (HY-101793). This product is intended for research and analytical applications. BMS-935177 is a potent and selective reversible inhibitor of Bruton’s tyrosine kinase (Btk) with an IC50 of 3 nM.
-
Poseltinib (Standard)
0 ImagesCat. No.: HY-109010RCAS No.: 1353552-97-2Synonyms: HM71224 (Standard); LY3337641 (Standard)Poseltinib (Standard) is the analytical standard of Poseltinib (HY-109010). This product is intended for research and analytical applications. Poseltinib (HM71224) is an orally active, selective, irreversible small molecule Bruton tyrosine Kinase (BTK) inhibitor. With an IC50 of 1.95 nM. Poseltinib effectively inhibits the signaling mediated by B cell receptors (BCR), Fc receptors (FcR), and Toll-like receptors (TLR). Poseltinib has anti-inflammatory activity and can be used in the research of rheumatoid arthritis.
-
(±)-Zanubrutinib (Standard)
0 ImagesCat. No.: HY-101474RCAS No.: 1633350-06-7Synonyms: (±)-BGB-3111 (Standard)(±)-Zanubrutinib (Standard) is the analytical standard of (±)-Zanubrutinib (HY-101474). This product is intended for research and analytical applications. (±)-Zanubrutinib ((±)-BGB-3111) is the racemate of Zanubrutinib (HY-101474A). (±)-Zanubrutinib inhibits Bruton's tyrosine kinase (Btk) with an IC50 of 0.63 nM.
-
(Rac)-IBT6A hydrochloride
0 ImagesCat. No.: HY-13036CCAS No.: 1807619-60-8(Rac)-IBT6A hydrochloride is a racemate of IBT6A hydrochloride. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM.
-
BTK IN-1 (Standard)
0 ImagesCat. No.: HY-101941RCAS No.: 1270014-40-8Synonyms: SNS062 analog (Standard)BTK IN-1 (Standard) is the analytical standard of BTK IN-1 (HY-101941). This product is intended for research and analytical applications. BTK IN-1 (SNS062 analog) is a potent BTK inhibitor, with an IC50 of <100 nM.
-
Elsubrutinib (Standard)
0 ImagesCat. No.: HY-109143RCAS No.: 1643570-24-4Synonyms: ABBV-105 (Standard)Elsubrutinib (Standard) is the analytical standard of Elsubrutinib (HY-109143). This product is intended for research and analytical applications. Elsubrutinib (ABBV-105) is an orally active, potent, selective and irreversible Bruton's tyrosine Kinase (BTK) inhibitor. The IC50 of Elsubrutinib for BTK catalytic domain is 0.18 μM. Elsubrutinib can be used for the research of inflammatory disease.
-
(R,R)-Birelentinib
0 ImagesCat. No.: HY-160167ACAS No.: 2662512-14-1Synonyms: (R,R)-DZD8586(R,R)-Birelentinib ((R,R)-DZD8586) (Compound 14) is a potent BTK inhibitor with IC50 values for BTK WT and BTK C481S of 0.7 and 0.86 nM, respectively. (R,R)-Birelentinib inhibits the self-phosphorylation of BTK and its IC50 is 24.3 nM. (R,R)-Birelentinib exhibits significant anti-proliferative activity against wild-type and C481S mutant HEK293 cells. (R,R)-Birelentinib can be used for the study of drug-resistant B-cell malignancies.
-
Vecabrutinib (Standard)
0 ImagesCat. No.: HY-109078RCAS No.: 1510829-06-7Synonyms: SNS-062 (Standard)Vecabrutinib (Standard) is the analytical standard of Vecabrutinib (HY-109078). This product is intended for research and analytical applications. Vecabrutinib (SNS-062) is a potent, noncovalent BTK and ITK inhibitor, with Kd values of 0.3 nM and 2.2 nM, respectively. Vecabrutinib shows an IC50 of 24 nM for ITK.
-
PF-06465469 (Standard)
0 ImagesCat. No.: HY-108691RCAS No.: 1407966-77-1PF-06465469 (Standard) is the analytical standard of PF-06465469 (HY-108691). This product is intended for research and analytical applications. PF-06465469 is a covalent inhibitor of ITK with an IC50 of 2 nM. PF-06465469 also inhibits BTK. PF-06465469 inhibits cell migration in response to CXCL12. PF-06465469 decreases PD-1 and LAG-3 expression. PF-06465469 can be used to study leukemia and T-cell lymphoma.
-
(R)-Elsubrutinib (Standard)
0 ImagesCat. No.: HY-109143BRCAS No.: 1643570-23-3Synonyms: (R)-ABBV-105 (Standard)(R)-Elsubrutinib (Standard) is the analytical standard of (R)-Elsubrutinib (HY-109143B). This product is intended for research and analytical applications. (R)-Elsubrutinib ((R)-ABBV-105) is a Btk inhibitor. (R)-Elsubrutinib can be used in studies of immune diseases (such as rheumatoid arthritis, psoriasis, ankylosing spondylitis, asthma, systemic lupus erythematosus) and cancer.
-
Evobrutinib (Standard)
0 ImagesCat. No.: HY-101215RCAS No.: 1415823-73-2Synonyms: M2951 (Standard); MSC2364447C (Standard)Evobrutinib (Standard) is the analytical standard of Evobrutinib (HY-101215). This product is intended for research and analytical applications. Evobrutinib (M2951) is an orally active, potent, highly selective and irreversibly covalent BTK inhibitor, with an IC50 of 8.9 nM. Evobrutinib (M2951) can be used for the research of autoimmune diseases.
-
ACP-5862-d4
0 ImagesCat. No.: HY-135334SACP-5862-d4 is deuterium labeled ACP-5862. ACP-5862 is a major active, circulating, pyrrolidine ring-opened metabolite of Acalabrutinib with an IC50 of 5.0 nM for Bruton tyrosine kinase (BTK). ACP‐5862 is a weak time‐dependent inactivator of CYP3A4 and CYP2C8. Acalabrutinib is an orally active, irreversible, and highly selective BTK inhibitor, with an IC50 of 3 nM and EC50 of 8 nM.
